Cover Image
Market Research Report

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 374679
Published Content info 76 Pages
Delivery time: 1-2 business days
Price
Back to Top
Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020
Published: April 30, 2020 Content info: 76 Pages
Description

Summary:

According to the recently published report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020'; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 12 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 5 and 1 respectively.

Report covers products from therapy areas Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Central Nervous System, Genetic Disorders, Immunology, Musculoskeletal Disorders, Ophthalmology, Infectious Disease, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Porphyria (Erythropoietic Protoporphyri), Rheumatoid Arthritis, Uveitis, Vitiligo, Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19), Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2371TDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
  • Aequus BioPharma Inc
  • Clinuvel Pharmaceuticals Ltd
  • Eton Pharmaceuticals Inc
  • Mallinckrodt Plc
  • Mitsubishi Tanabe Pharma Corp
  • Palatin Technologies Inc
  • SynAct Pharma AB
  • Viewpoint Molecular Targeting LLC
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
  • afamelanotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AP-1189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AQB-565 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • corticotropin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • corticotropin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CUV-9900 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dersimelagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Parvysmelanotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Antagonize MCR1 for Metastatic Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-8177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-8331 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-9643 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 23, 2020: SCENESSE to be Prescribed in China
  • Apr 16, 2020: First US patients to be treated with SCENESSE
  • Apr 16, 2020: Innovative drug launched for rare, isolating, "light intolerance" disorder
  • Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
  • Apr 03, 2020: SynAct Pharma applies for patent for AP1189 within COVID-19
  • Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
  • Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
  • Mar 16, 2020: Mallinckrodt confirms court decision in lawsuit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and provides update related to global opioid settlement and present financing activities
  • Mar 05, 2020: Data on Acthar Gel (repository corticotropin injection) therapy in immunoglobulin a nephropathy (IgAN) published in Kidney International Reports
  • Mar 04, 2020: Mallinckrodt announces publication of new data on Acthar Gel (Repository Corticotropin Injection) in rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis published in Open Access Rheumatology: Research and Reviews
  • Mar 03, 2020: FDA meeting confirmed to advance SCENESSE in vitiligo
  • Mar 02, 2020: Supply of Scenesse unaffected by coronavirus
  • Feb 27, 2020: Mallinckrodt to present new data from two studies on Acthar Gel (Repository Corticotropin Injection) therapy in Multiple Sclerosis (MS) relapse at Fifth Annual ACTRIMS Forum 2020
  • Feb 19, 2020: Palatin Technologies announces first patient enrolled in dry eye disease phase 2 clinical trial with PL9643
  • Feb 10, 2020: Request for FDA guidance meeting SCENESSE in Vitiligo
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Aequus BioPharma Inc, H1 2020
  • Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2020
  • Pipeline by Eton Pharmaceuticals Inc, H1 2020
  • Pipeline by Mallinckrodt Plc, H1 2020
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
  • Pipeline by Palatin Technologies Inc, H1 2020
  • Pipeline by SynAct Pharma AB, H1 2020
  • Pipeline by Viewpoint Molecular Targeting LLC, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Back to Top